FAS and ovarian carcinoma: Cisplatin can affect membrane fluidity through the activation of the Fas/Fas-L death pathway [55], and the dysregulation of the Fas/Fas-L system may be an important determinant of cisplatin_resistance in ovarian epithelial cancer cells [46].